Reducing alcohol use and improving HIV treatment for men in fishing communities
Kisoboka: Reducing Hazardous Alcohol Use and Optimizing Treatment as Prevention Among Men Living With HIV in Risk Environments
This study is testing a new program to help men with HIV in fishing communities cut down on drinking and stick to their HIV treatment to improve their health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 716 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | San Diego State University Academic / other |
| Locations | 1 site (Kampala) |
| Trial ID | NCT06771843 on ClinicalTrials.gov |
What this trial studies
This intervention focuses on men living with HIV in fishing communities who engage in hazardous alcohol use. The Kisoboka intervention aims to reduce alcohol consumption and enhance adherence to antiretroviral therapy (ART) through behavioral economics and motivational interviewing techniques. By addressing the unique social and structural challenges in these environments, the study seeks to improve health outcomes and achieve undetectable HIV viral loads. Participants will be screened and referred for support based on their alcohol use and treatment adherence.
Who should consider this trial
Good fit: Ideal candidates for this study are men living with HIV who reside in fishing communities and exhibit hazardous drinking behaviors.
Not a fit: Patients who are not living with HIV or do not engage in hazardous alcohol use may not benefit from this intervention.
Why it matters
Potential benefit: If successful, this intervention could significantly improve health outcomes for men living with HIV by reducing alcohol use and enhancing adherence to HIV treatment.
How similar studies have performed: Other studies have shown promise in using behavioral economics and motivational interviewing to improve health outcomes, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. living with HIV; 2. residing in a fishing community (on most days/nights); 3. AUDIT-C positive (≥4) indicating potential hazardous drinking; 4. \>6 months since initial antiretroviral treatment (ART) initiation; 5. not planning to move from the area within the next 6 months; 6. have their own mobile phone and can be reached via phone. 7. an indicator of potential suboptimal treatment as prevention (TasP) either: (i) last HIV viral load test (within 6 months) was detectable (\>20) or (ii) last viral load test between 6 and 13 months ago was detectable (\>20) and reports missing ≥2 ART doses in the past 2 weeks or (iii) a lack of viral load test results for the prior 13 months in clinic records and reports missing ≥2 ART doses in the past 2 weeks; Exclusion Criteria: 1. visibly intoxicated at enrollment (eligible to enroll when not intoxicated); 2. does not speak Luganda or English; 3. currently receiving a majority of work payments via mobile money/digital payments; 4. participated in the Kisoboka pilot RCT; 5. unable to read basic Luganda or English
Where this trial is running
Kampala
- Makerere University Walter Reed Program affiliated sites in Buikwe, Nakasongola, Mukono, and Kayunga Districts — Kampala, Uganda (Recruiting)
Study contacts
- Principal investigator: Susan M Kiene, PhD, MPH — San Diego State University
- Study coordinator: Joseph Matovu, PhD, MHS
- Email: jmatovu@musph.ac.ug
- Phone: +256 414 543872
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.